SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-056925
Filing Date
2024-05-09
Accepted
2024-05-09 16:08:05
Documents
12
Period of Report
2024-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnth-20240509.htm   iXBRL 8-K 43558
2 EX-99.1 dnth-ex99_1.htm EX-99.1 146582
  Complete submission text file 0000950170-24-056925.txt   357658

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dnth-20240509.xsd EX-101.SCH 57485
15 EXTRACTED XBRL INSTANCE DOCUMENT dnth-20240509_htm.xml XML 4698
Mailing Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139
Business Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Dianthus Therapeutics, Inc. /DE/ (Filer) CIK: 0001690585 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38541 | Film No.: 24930554
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)